Ganoderma lucidum(Reishi mushroom) for cancer treatment

医学 传统医学 癌症 不利影响 替代医学 临床试验 灵芝 安慰剂 荟萃分析 梅德林 中医药 随机对照试验 内科学 病理 政治学 法学
作者
Xingzhong Jin,Julieta Ruíz Beguerie,Daniel Man-yeun Sze,Gcf Chan
出处
期刊:Cochrane Database of Systematic Reviews [Elsevier BV]
被引量:68
标识
DOI:10.1002/14651858.cd007731.pub2
摘要

Background Ganoderma lucidum is a natural medicine that is widely used and recommended by Asian physicians and naturopaths for its supporting effects on immune system. Laboratory research and a handful of preclinical trials have suggested that G. lucidum carries promising anticancer and immunomodulatory properties. The popularity of taking G. lucidum as an alternative medicine has been increasing in cancer patients. However, there is no systematic review that has been conducted to evaluate the actual benefits of G. lucidum in cancer treatment. Objectives To evaluate the clinical effects of G. lucidum on long‐term survival, tumour response, host immune functions and quality of life in cancer patients, as well as adverse events associated with its use. Search methods The authors ran an extensive set of databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, NIH, AMED, CBM, CNKI, CMCC and VIP Information/Chinese Scientific Journals Database was searched for randomised controlled trials (RCTs) in October 2011. Other strategies used were scanning the references of articles retrieved, handsearching of the International Journal of Medicinal Mushrooms and contact with herbal medicine experts and manufacturers of G. lucidum. Selection criteria To be eligible for being included in this review, studies had to be RCTs comparing the efficacy of G. lucidum medications to active or placebo control in patients with cancer that had been diagnosed by pathology. All types and stages of cancer were eligible for inclusion. Trials were not restricted on the basis of language. Data collection and analysis Five RCTs met the inclusion criteria and were included in this review. Two independent review authors were assigned to assess the methodological quality of individual trials. Common primary outcomes were tumour response evaluated according to the World Health Organization (WHO) criteria, immune function parameters such as natural killer (NK)‐cell activity and T‐lymphocyte co‐receptor subsets, and quality of life measured by the Karnofsky scale score. No trial had recorded long‐term survival rates. Associated adverse events were reported in one study. A meta‐analysis was performed to pool available data from the primary trials. Results were gauged using relative risks (RR) and standard mean differences (SMD) for dichotomous and continuous data respectively, with a 95% confidence interval (CI). Main results The methodological quality of primary studies was generally unsatisfying and the results were reported inadequately in many aspects. Additional information was not available from primary trialists. The meta‐analysis results showed that patients who had been given G. lucidum alongside with chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone (RR 1.50; 95% CI 0.90 to 2.51, P = 0.02). G. lucidum treatment alone did not demonstrate the same regression rate as that seen in combined therapy. The results for host immune function indicators suggested that G. lucidum simultaneously increases the percentage of CD3, CD4 and CD8 by 3.91% (95% CI 1.92% to 5.90%, P < 0.01), 3.05% (95% CI 1.00% to 5.11%, P < 0.01) and 2.02% (95% CI 0.21% to 3.84%, P = 0.03), respectively. In addition, leukocyte, NK‐cell activity and CD4/CD8 ratio were marginally elevated. Four studies showed that patients in the G. lucidum group had relatively improved quality of life in comparison to controls. One study recorded minimal side effects, including nausea and insomnia. No significant haematological or hepatological toxicity was reported. Authors' conclusions Our review did not find sufficient evidence to justify the use of G. lucidum as a first‐line treatment for cancer. It remains uncertain whether G. lucidum helps prolong long‐term cancer survival. However, G. lucidum could be administered as an alternative adjunct to conventional treatment in consideration of its potential of enhancing tumour response and stimulating host immunity. G. lucidum was generally well tolerated by most participants with only a scattered number of minor adverse events. No major toxicity was observed across the studies. Although there were few reports of harmful effect of G. lucidum, the use of its extract should be judicious, especially after thorough consideration of cost‐benefit and patient preference. Future studies should put emphasis on the improvement in methodological quality and further clinical research on the effect of G. lucidum on cancer long‐term survival are needed. An update to this review will be performed every two years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
吃不饱发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
英吉利25发布了新的文献求助10
2秒前
Mess发布了新的文献求助10
4秒前
4秒前
jase完成签到,获得积分20
4秒前
萝卜发布了新的文献求助10
4秒前
金子发布了新的文献求助10
5秒前
Esther完成签到,获得积分20
5秒前
葉深完成签到,获得积分20
5秒前
午凌二发布了新的文献求助10
5秒前
完美世界的应助被虎王采纳,获得10
6秒前
寒冷白萱完成签到 ,获得积分10
6秒前
6秒前
酷酷飞烟发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
友好的罡发布了新的文献求助10
7秒前
Hi完成签到,获得积分10
7秒前
8秒前
tbb完成签到,获得积分10
8秒前
李木子发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
研友_VZG7GZ的应助被小浪矢采纳,获得10
10秒前
10秒前
微笑大螃蟹完成签到,获得积分10
10秒前
11秒前
田様的应助被花花采纳,获得10
11秒前
xbs发布了新的文献求助10
11秒前
12秒前
蜉蝣发布了新的文献求助30
12秒前
12秒前
赫江涛发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192338
求助须知:如何正确求助?哪些是违规求助? 9578893
关于积分的说明 21862760
捐赠科研通 7791869
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483759